Despite some ongoing patent battles and mounting legal trouble, Myriad Genetics remains a heavy hitter in the world of cancer diagnostics, and now the Utah company has struck up a deal with drug developer BioMarin Pharmaceutical to use one of its molecular tests to develop a targeted cancer drug.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
If you ask Carl Goldfischer, companion diagnostic tests are a bright spot in the overall diagnostics industry right now. "The areas most interesting are companion diagnostics with specific forms...
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Sysmex and Bayer struck a deal that takes personalized medicine yet another step forward. The Japanese diagnostics giant and the German drugmaker will develop companion diagnostic tests designed for targeted cancer tumor treatments. Neither side is disclosing financial details, but they'll carry out their agreement through subsidiaries.
Bayer, the German drugmaker, will join forces with Japanese diagnostics giant Sysmex to develop companion diagnostics tests for targeted cancer tumor treatments. Specifically, Sysmex's newly-acquired Inostics division will develop blood-based companion diagnostic tests to be paired with targeted anti-cancer drugs advanced by Bayer HealthCare.
Advanced Cell Diagnostics has scored a major deal to expand the reach of its molecular pathology RNA biomarker test tech around the world. In a boon for the California company, Life Technologies has agreed to sell Advanced Cell Diagnostics' RNAscope series of probes and diagnostic kits to researchers through its global distribution network.
Roche's Ventana Medical Systems division will link up with Germany's Boehringer Ingelheim to develop companion diagnostic tests for new cancer drugs. Neither side is disclosing financial details, but the deal is the latest example of how personalized medicine now routinely links the drug development and diagnostics worlds.
Roche's Ventana Medical Systems arm gained pivotal Chinese regulatory approval for a companion diagnostic that pairs with Pfizer's targeted lung cancer drug Xalkori.
Massachusetts diagnostics outfit Nuclea Biotechnologies is snatching up the U.S. subsidiary of Germany's Wilex AG, a biopharma focused on developing diagnostic and drug candidates for cancer. Buyer and seller will also forge a tighter development alliance as part of the deal.